Death with COVID of the immunocompromised and vulnerable delayed, and perhaps by not very much, but probably not avoided:: BioNTech never made claims of vaccine durability, and never claimed that its vaccine could prevent severe cases or hospitalisation, or protect the immunocompromised and vulnerable

 by Ganesh Sahathevan 

There has been much talk about how first, vaccines were meant to prevent death, severe cases and hospitalisation, and simultaneously, how  regular booster shots will be required to maintain immunity.

These are not claims made BioNTech (see story below). Instead, these are claims that are being made by governments and civil servants, after the fact, in an apparent attempt to justify the purchase of vaccines from the handful of companies in the first place.

Therefore, it is not unlikely that death, severe cases and hospitalisation, especially among the  immunocompromised and vulnerable has only been delayed, and perhaps by not very much.

The issue for the community as large is how much more is to be spent in protecting this group. As reported, AUD 500 Billion, mostly in borrowed money, has already been spent. 

TO BE READ WITH 

Sunday, September 5, 2021

BioNTech says two doses of its vaccine provide maximum protection-Hospitalisation, less severe cases, spike in cases, are signs of vaccine failure and not of the vaccine working

by Ganesh Sahathevan 

More from BioNTech's SEC filings:

On November 18, 2020, we and Pfizer announced that, after conducting the final efficacy analysis in our ongoing Phase 3 study, BNT162b2 met all of the study’s primary efficacy endpoints. In this pivotal Phase 3 trial of BNT162b2, there were over 44,000 participants who were 16 years and older, 21,720 of whom received the two-dose regimen of 30 μg BNT162b2, which was given 21 days apart, and 21,728 of whom received the placebo. Among 36,523 participants who had no evidence of existing or prior SARS-CoV-2 infection at the time of the immunizations, there were 170 cases of COVID-19 observed at least seven days after the second dose. Of these 170 cases of COVID-19, 162 cases occurred among placebo recipients and eight cases occurred in vaccine recipients, corresponding to 95.0% vaccine efficacy. Among participants with and without evidence of prior SARS CoV-2 infection, there were nine cases of COVID-19 among vaccine recipients and 169 among placebo recipients, corresponding to a 94.6% vaccine efficacy. The cumulative incidence of COVID-19 cases over time among placebo and vaccine recipients began to diverge by 12 days after the first dose, and 52.4% vaccine efficacy was observed between the first and second doses, indicating the early onset of a partially protective effect of immunization. Two doses of vaccine provide the maximum protection observed. Ten cases of severe COVID-19 were observed with onset after the first dose. Nine cases occurred among placebo recipients and one among BNT162b2 recipients.

Meanwhile government leaders everywhere, the latest being the NSW Premier Gladys Berejiklian, insist that all vaccines including the Pfizer BioNTech are working, for they prevent the severe cases that require hospitalisation. That is not what BioNTech claimed.

TO BE READ WITH 

Saturday, August 28, 2021

Pfizer/ BioNTech warned investors that the durability of the immune response of its COVID vaccine had " not yet been demonstrated in clinical trials"-US SEC disclosure by BioNTech calls for investigation into Scott Morrison, Daniel Andrews, and Gladys Berekilian's promotion of Pfizer/ BioNTech

 by Ganesh Sahathevan 

Prime Minister Scott Morrison had his Covid jab in February 2021.

The developer of the Pfizer COVID vaccine, Comirnaty,
BioNTech SE has lodged documents at the US Securities and Exchange Commission (SEC), pursuant to US securities disclosure laws.

The documents include BioNTech SE's annual report for the year ended 31 December 2021 It includes this statement which is among a range of cautionary statements that the company is bound by law to alert investors to:

"......the durability of (the) immune response generated by our COVID-19 vaccine....has not yet been demonstrated in clinical trials........."

This is an important issue for investors for a vaccine with limited durability is not going to sell well, if at all.  Taxpayers would not be willing to spend billions on a vaccine that provides protection for only a relatively short  amount of time. 

However, in Australia, we have in fact seen the Prime Minister, Scott Morrison,  and the state leaders in particular  Premier Daniel Andrews of Victoria  and Premier Gladys Berekilian of NSW  promoting  the  Pfizer/ BioNTech COVID vaccine, as if it were guaranteed to provide life long protection. In the process they have expanded billions. Taxpayers are entitled to an explanation.

END